|
||||||
Executive Summary Gastric Ulcers-Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers-Pipeline Review, H2 2018, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or vomiting and unexplained weight loss. Predisposing factors include smoking and alcoholism. Treatment includes antibiotics and antacids. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Ulcers-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Gastric Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Gastric Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Ulcers (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Gastric Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Gastric Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Gastric Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Ulcers (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Gastric Ulcers (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Gastric Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Read More Contact Us:
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Gastric Ulcers-Overview Gastric Ulcers-Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Gastric Ulcers-Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Gastric Ulcers-Companies Involved in Therapeutics Development Boryung Pharmaceutical Co Ltd Daewoong Pharmaceutical Co Ltd Kukje Pharmaceutical Industry Co Ltd RaQualia Pharma Inc XuanZhu Pharma Co Ltd Gastric Ulcers-Drug Profiles (lafutidine + irsogladine maleate)-Drug Profile Product Description Mechanism Of Action R&D Progress DWJ-1386-Drug Profile Product Description Mechanism Of Action R&D Progress DWP-14012-Drug Profile Product Description Mechanism Of Action R&D Progress KBP-3571-Drug Profile Product Description Mechanism Of Action R&D Progress KJ-14001-Drug Profile Product Description Mechanism Of Action R&D Progress PMKS-005-Drug Profile Product Description Mechanism Of Action R&D Progress SFR-9X0123-Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit COX-2 for Gastric Ulcers, Inflammation and Pain-Drug Profile Product Description Mechanism Of Action R&D Progress tegoprazan-Drug Profile Product Description Mechanism Of Action R&D Progress Gastric Ulcers-Dormant Projects Gastric Ulcers-Discontinued Products Gastric Ulcers-Product Development Milestones Featured News & Press Releases Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc. Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) Jun 01, 2007: AstraZeneca's Prilosec Patents Upheld By Court Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals Oct 23, 2001: Prilosec US litigation May 02, 2001: AstraZeneca Receives Six Months' Market Exclusivity for Prilosec May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent Apr 23, 2001: AstraZeneca Files Lawsuit against Apotex Corporation and Torpharm for Patent Infringement Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Figures Number of Products under Development for Gastric Ulcers, H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products by Targets, H2 2018 Number of Products by Stage and Targets, H2 2018 Number of Products by Top 10 Mechanism of Actions, H2 2018 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 Number of Products by Stage and Routes of Administration, H2 2018 Number of Products by Molecule Types, H2 2018 Number of Products by Stage and Molecule Types, H2 2018 List of Tables Number of Products under Development for Gastric Ulcers, H2 2018 Number of Products under Development by Companies, H2 2018 Number of Products under Development by Universities/Institutes, H2 2018 Products under Development by Companies, H2 2018 Products under Development by Universities/Institutes, H2 2018 Number of Products by Stage and Target, H2 2018 Number of Products by Stage and Mechanism of Action, H2 2018 Number of Products by Stage and Route of Administration, H2 2018 Number of Products by Stage and Molecule Type, H2 2018 Gastric Ulcers-Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018 Gastric Ulcers-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018 Gastric Ulcers-Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018 Gastric Ulcers-Pipeline by RaQualia Pharma Inc, H2 2018 Gastric Ulcers-Pipeline by XuanZhu Pharma Co Ltd, H2 2018 Gastric Ulcers-Dormant Projects, H2 2018 Gastric Ulcers-Discontinued Products, H2 2018 Single User License: Site License: Corporate User License: Boryung Pharmaceutical Co Ltd Daewoong Pharmaceutical Co Ltd Kukje Pharmaceutical Industry Co Ltd RaQualia Pharma Inc XuanZhu Pharma Co Ltd Gastric Ulcers Therapeutic Products under Development, Key Players in Gastric Ulcers Therapeutics, Gastric Ulcers Pipeline Overview, Gastric Ulcers Pipeline, Gastric Ulcers Pipeline Assessment |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara" |